Showing results (1-10 of 168) with videos related to
Sort By:
Pageof 17
Drug Design, Development and Therapy|November 25, 2014
The role of health technology assessment bodies in shaping drug developmentOriana Ciani, Claudio JommiApplied Health Economics and Health Policy|November 26, 2022
EQ-5D-5L Population Norms for ItalyMichela Meregaglia, Francesco Malandrini, Aureliano Paolo Finch, et al.Social Science & Medicine (1982)|November 5, 2021
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administrationAureliano Paolo Finch, Michela Meregaglia, Oriana Ciani, et al.BMC Health Services Research|May 13, 2023
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.Medicina (Kaunas, Lithuania)|June 27, 2025
Obesity in Italy: An Empirical Analysis of Healthcare Consumption, Quality of Life and ComorbiditiesElenka Brenna, Claudio JommiPharmacoeconomics - Open|February 10, 2023
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal ConsistencyClaudio Jommi, Carlotta GaleoneClinical Therapeutics|January 15, 2020
Value Lies in the Eye of the Patients: The Why, What, and How of Patient-reported Outcomes MeasuresOriana Ciani, Carlo Baldassarre FedericiHealth Policy (Amsterdam, Netherlands)|July 11, 2006
Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-studyClaudio Jommi, Silvia ParuzzoloHealth Policy (Amsterdam, Netherlands)|February 28, 2012
Stakeholders involvement by HTA Organisations: why is so different?Marianna Cavazza, Claudio JommiPharmacoeconomics|December 20, 2007
The last decade of Italian pharmaceutical policy: instability or consolidation?Giovanni Fattore, Claudio JommiPageof 17